

How can I learn more about the HORIZON trial?

It's easy!

If you think you understand the entry criteria listed in this brochure and want to participate in the HORIZON trial you can contact your local study research team.

If you or someone you care about meets the trial entry criteria you can also contact the HSG or EHDN directly;

HSG toll-free number: 1 (800) 487 7671

EHDN Phone: + 49 731 5006 3103

or by visiting the web at:

www.Huntington-Study-Group.org

www.euro-hd.net

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild-to-Moderate Huntington Disease

RSRB-University of Rochester-Approval
RSRB No. 27754
Expires May 13, 2010
- jtg - 5/21/09

The Huntington Study Group and European Huntington's Disease Network

The Huntington Study Group (HSG) and the European Huntington's Disease Network (EHDN) are international associations of clinical investigators, coordinators, scientists and staff from participating hospitals and universities in North America, Europe, Australia and New Zealand.

The HSG and EHDN strive to advance knowledge about the cause, process and clinical impact of HD in order to develop and test promising therapeutic interventions.

For more information please visit:

www.Huntington-Study-Group.org

www.euro-hd.net

www.horizontrial.com

HORIZON Steering Committee

Karl Kieburtz - **Principal Investigator**

Bernhard Landwehrmeyer - **co-Principal Investigator**

Merit Cudkowicz

Ray Dorsey

Andrew Feigin

Victoria Hunt

Elise Kayson

Michael McDermott

Sarah Noonberg

Wendy Seitz

Paola Soliveri

Jennifer Thompson

Francis Walker

HORIZON
A Huntington Disease Investigational Trial

A clinical trial conducted by the HSG and EHDN under the sponsorship of Medivation, Inc in collaboration with Pfizer, Inc.

H•S•G HUNTINGTON'S DISEASE NETWORK **HD**
HUNTINGTON • STUDY • GROUP

About Clinical Trials

What is a clinical trial?

A clinical trial is a study to evaluate promising experimental treatments. Trials are designed to learn if new medications are safe, tolerable and effective. A clinical trial differs from an observational study in which people are examined over time without receiving any experimental drugs or treatments.

What is the HORIZON trial?

The Huntington Study Group (HSG) and European Huntington's Disease Network (EHDN) are conducting a trial of the research medication Dimebon in persons who have clinical features of Huntington Disease (HD). HORIZON is designed to determine the safety of Dimebon 60 mg per day versus placebo and to determine whether or not there is an effect on cognitive (thinking) abilities. The goal of the trial is to confirm the positive results of an earlier HD study. The study will also evaluate other HD symptoms including motor (movement), and overall functioning in people with HD when Dimebon is taken over a period of 6 months. Approximately 50 research centers across North America, Europe, and Australia will enroll approximately 350 individuals. This trial is sponsored by Medivation, Inc in collaboration with Pfizer Inc.

About the HORIZON Trial

RSRB-University of Rochester-Approval
RSRB No. 27754
Expires May 13, 2010
-jtg - 5/21/09

Who can participate in HORIZON?

In order to qualify for participation in the HORIZON trial you must:

- Be at least 30 years old or more
- Be able to provide written informed consent
- Have clinical features of HD and have tested positive for the HD gene
- Have some difficulty with cognitive (thinking) abilities
- Have a caregiver who assists/spends at least 5 days for at least 3 hours per day with you
- Be able to take oral medication and be willing to comply with study-specific procedures
- Not be pregnant, lactating or intend to become pregnant

Further information on participation will be provided to you by your local study research team.

What are the study procedures?

If you are interested in participating in the HORIZON trial you will first have a visit with the study team to determine if you are eligible to participate. If you qualify, then you will have a second visit to evaluate your general health, mood, thinking abilities, memory and movement. You and your caregiver will also be asked questions about how you are functioning. Blood samples will be taken at both of these visits.

During the trial you will be assigned randomly to receive either 60 mg per day of active study drug (Dimebon), or a pill that looks like the study drug but has no active ingredients (placebo). You will continue to take the study drug or placebo for a total of 26 weeks. Should you complete the trial you will be eligible to receive Dimebon at the conclusion of the trial. If you chose not to continue to receive Dimebon your total participation time will be 30 weeks. There are 8 visits and 1 telephone call scheduled for this trial to evaluate your general health, thinking abilities, memory, mood, overall functioning and movement.

What are the risks associated with participation in HORIZON?

There are mild risks associated with taking blood samples that include pain or bruising at the site where the blood is taken. Some of the side effects seen with this medication in a prior HD study include, headache and sleepiness. Further details on these and other risks are explained in the consent form. Please ask your local study research team if you have any questions or concerns.

What are the benefits to me if I decide to participate in HORIZON?

While there may be no direct benefit to you from participating in the HORIZON trial, you will be contributing to the growing knowledge about Huntington Disease.